Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial-Reference-Cited by-同舟云学术

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

Published:2014-11 Issue:12 Volume:10 Page:3435-3445
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Einstein Mark H¹,Takacs Peter²,Chatterjee Archana³,Sperling Rhoda S⁴,Chakhtoura Nahida²,Blatter Mark M⁵,Lalezari Jacob⁶,David Marie-Pierre⁷,Lin Lan⁸,Struyf Frank⁷,Dubin Gary⁹

Affiliation:

1. Montefiore Medical Center and Albert Einstein College of Medicine; Obstetrics & Gynecology and Women's Health; Bronx, NY USA

2. University of Miami; Obstetrics and Gynecology; Miami, FL USA

3. University of South Dakota Sanford School of Medicine; Sanford Children's Specialty Clinics; Sioux Falls, SD USA

4. Icahn School of Medicine at Mount Sinai; Department of Obstetrics; Gynecology, and Reproductive Science; New York, NY USA

5. Pediatric Alliance; Pittsburgh, PA USA

6. Quest Clinical Research; San Francisco, CA USA

7. GlaxoSmithKline Vaccines; Wavre, Belgium

8. XPE Pharma & Science; Wavre, Belgium, on behalf of GlaxoSmithKline Vaccines

9. GlaxoSmithKline Biologicals; King of Prussia, PA USA

Publisher

Informa UK Limited